

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
18 November 2004 (18.11.2004)

PCT

(10) International Publication Number
WO 2004/098713 A3

(51) International Patent Classification⁷: **A61P 9/00**,
A61K 31/4365, 31/60

(21) International Application Number:
PCT/US2004/011257

(22) International Filing Date: 26 April 2004 (26.04.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/467,903 5 May 2003 (05.05.2003) US

(71) Applicant (for all designated States except US): **ELI LILLY AND COMPANY** [US/US]; Lilly Corporate Center, Indianapolis, Indiana 46285 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BRANDT, John**, Thomas [US/US]; 7330 Royal Oakland Drive, Indianapolis, Indiana 46236 (US). **FARID, Nagy, Alphonse** [US/US]; 810 Millerwood Drive, Lebanon, Indiana 46052 (US). **JAKUBOWSKI, Joseph, Anthony** [US/US]; 3740 Governors Road, Indianapolis, Indiana 46208 (US). **WINTERS, Kenneth, John** [US/US]; 3342 Kenney Drive East, Germantown, Tennessee 38139 (US).

(74) Agents: **GINAH, Francis, O.** et al.; Patent Division, Eli Lilly and Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

— as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,

[Continued on next page]

(54) Title: TREATING CARDIOVASCULAR DISEASES WITH A COMPOUND OF FORMULA (I) (CS 747 - PRASUGREL; RN 150322-43-4)



(57) Abstract: A method of treating Cardiovascular Diseases comprising administering of a compound of formula (I) (chemical names i.a. CS747 or Prasugrel; registry number 150322-43-3) or a pharmaceutically acceptable salt, solvate, prodrug, active metabolite, racemate or enantiomer thereof, in conjunction with coronary and non-coronary intervention procedures is disclosed.



IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG)

— of inventorship (Rule 4.17(iv)) for US only

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:
29 December 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US2004/011257

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61P9/00 A61K31/4365 A61K31/60

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, PAJ, WPI Data, CHEM ABS Data, BIOSIS, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 01/44239 A (BRISTOL MYERS SQUIBB CO ; MURUGESAN NATESAN (US); GU ZHENGXIANG (US);) 21 June 2001 (2001-06-21) page 1, lines 7-9 page 48, lines 9,24,25 sentence bridging page 48 and page 49 page 53, lines 25,26 page 54, lines 4,5	1-14
X	WO 02/04461 A (YAMAMURA NAOTOSHI ; SANKYO CO (JP); ASAI FUMITOSHI (JP); INOUE TERUHIK) 17 January 2002 (2002-01-17) abstract page 3	1-14

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

14 October 2004

Date of mailing of the international search report

09/11/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Baumgärtner, H

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US2004/011257

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 02/051412 A (SANKYO CO ; ASAI FUMITOSHI (JP); INOUE TERUHIKO (JP); OGAWA TAKETOSHI) 4 July 2002 (2002-07-04) abstract page 3	1-14
X	WO 97/49397 A (SANKYO CO ; ASAI FUMITOSHI (JP); INOUE TERUHIKO (JP); OGAWA TAKETOSHI) 31 December 1997 (1997-12-31) abstract	1-14
X	EP 1 298 132 A (SANKYO CO ; UBE INDUSTRIES (JP)) 2 April 2003 (2003-04-02) page 2 '0001!', '0007!', '0008!	1-14

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US2004/011257

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0144239	A	21-06-2001	AU 2092601 A CA 2395088 A1 EP 1237888 A2 JP 2003520785 T WO 0144239 A2 US 2004127515 A1 US 2004106833 A1 US 2002143024 A1	25-06-2001 21-06-2001 11-09-2002 08-07-2003 21-06-2001 01-07-2004 03-06-2004 03-10-2002
WO 0204461	A	17-01-2002	AU 6791601 A BR 0112168 A CA 2415558 A1 CN 1452624 T CZ 20030018 A3 EP 1298132 A1 HU 0301645 A2 WO 0204461 A1 JP 2002145883 A NO 20030022 A US 2003134872 A1	21-01-2002 02-09-2003 17-01-2002 29-10-2003 14-05-2003 02-04-2003 29-09-2003 17-01-2002 22-05-2002 05-03-2003 17-07-2003
WO 02051412	A	04-07-2002	BR 0116531 A CA 2432644 A1 CZ 20031660 A3 EP 1350511 A1 HU 0400644 A2 WO 02051412 A1 JP 2002255814 A NO 20032902 A SK 7542003 A3 US 2004024013 A1	25-02-2004 04-07-2002 17-12-2003 08-10-2003 28-06-2004 04-07-2002 11-09-2002 24-06-2003 02-12-2003 05-02-2004
WO 9749397	A	31-12-1997	AU 3191597 A WO 9749397 A1 JP 10310586 A	14-01-1998 31-12-1997 24-11-1998
EP 1298132	A	02-04-2003	AU 6791601 A BR 0112168 A CA 2415558 A1 EP 1298132 A1 HU 0301645 A2 NO 20030022 A US 2003134872 A1 CN 1452624 T CZ 20030018 A3 WO 0204461 A1 JP 2002145883 A	21-01-2002 02-09-2003 17-01-2002 02-04-2003 29-09-2003 05-03-2003 17-07-2003 29-10-2003 14-05-2003 17-01-2002 22-05-2002


INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2004/011257

Box No. IV Text of the abstract (Continuation of item 5 of the first sheet)

A method of treating Cardiovascular Diseases comprising administering of a compound of formula I (chemical names i.a. CS747 or Prasugrel; registry number 150322-43-3)



I

or a pharmaceutically acceptable salt, solvate, prodrug, active metabolite, racemate or enantiomer thereof, in conjunction with coronary and non-coronary intervention procedures is disclosed.